Company Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 12:19:20 2024-05-24 EDT			5-day change	1st Jan Change
5.625 ^USD	-0.27%		-6.00%	+20.77%

05-23	Zura Bio Insider Bought Shares Worth $496,000, According to a Recent SEC Filing	MT
05-10	Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating	MT

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Number of employees: 15

Managers	Title	Age	Since
Someit Sidhu FOU	Founder	34	22-01-17
Robert Lisicki CEO	Chief Executive Officer	57	01-07
Verender Badial DFI	Director of Finance/CFO	51	23-02-28
Gary Whale CTO	Chief Tech/Sci/R&D Officer	50	23-01-31
Michael Howell CTO	Chief Tech/Sci/R&D Officer	47	22-11-30
Kimberly Ann Davis IRC	Investor Relations Contact	56	22-08-31
Harjit Singh PRN	Corporate Officer/Principal	-	-
Marlyn Mathew AUD	Comptroller/Controller/Auditor	-	-
Dave Brady PRN	Corporate Officer/Principal	-	-
Theresa Lowry HRO	Human Resources Officer	50	-

Members of the board	Title	Age	Since
Amit Munshi CHM	Chairman	56	23-02-28
Steven Schoch BRD	Director/Board Member	64	23-02-28
Sandeep Kulkarni BRD	Director/Board Member	43	22-02-28
Jennifer Jarrett BRD	Director/Board Member	53	22-12-31
Parvinder Thiara BRD	Director/Board Member	39	23-05-31
Robert Lisicki CEO	Chief Executive Officer	57	01-07
Someit Sidhu FOU	Founder	34	22-01-17
Neil Graham BRD	Director/Board Member	65	22-12-31
Arnout Ploos van Amstel BRD	Director/Board Member	58	11-08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	63,683,806	37,613,075 ( 59.06 %)	0	59.06 %

Name	Equities	%	Valuation
Venrock Associates 13.82 %	6,023,166	13.82 %	22 M $
Chris Kim 12.40 %	5,404,274	12.40 %	20 M $
Athanor Capital LP 11.01 %	4,801,633	11.01 %	17 M $
Someit Sidhu 8.430 %	3,675,047	8.430 %	13 M $
Deep Track Capital LP 7.633 %	3,327,375	7.633 %	12 M $
RA Capital Management LP 7.381 %	3,217,503	7.381 %	12 M $
Borade Shashibhushan 7.289 %	3,177,623	7.289 %	12 M $
PFIZER, INC. 6.813 %	2,970,022	6.813 %	11 M $
Suvretta Capital Management LLC 6.538 %	2,850,000	6.538 %	10 M $
Jeffrey Robert Jay 6.326 %	2,757,740	6.326 %	10 M $

Name	Equities	%	Valuation
Highbridge Capital Management LLC -	839,019	-	254 223 $
Hudson Bay Capital Management LP -	199,975	-	60 592 $
Boussard & Gavaudan Investment Management LLP -	187,500	-	56 813 $
Kim LLC -	125,000	-	37 875 $
Meteora Capital LLC -	97,231	-	29 461 $
Polar Asset Management Partners, Inc. -	75,071	-	22 747 $
Whitebox Advisors LLC -	75,000	-	22 725 $
Walleye Capital LLC -	56,608	-	17 152 $
Clear Street LLC -	45,675	-	13 840 $
Walleye Trading LLC -	31,842	-	9 648 $

Zura Bio Ltd.

1489 West Warm Springs Road Suite 110

89014, Henderson

http://www.zurabio.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.64 USD

Average target price

19.75 USD

Spread / Average Target

+250.18%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ZURA BIO LIMITED	+20.77%	352M
VERTEX PHARMACEUTICALS INCORPORATED	+12.07%	116B
REGENERON PHARMACEUTICALS, INC.	+12.98%	106B
BIONTECH SE	-9.23%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-14.49%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+6.70%	14.14B
SAREPTA THERAPEUTICS, INC.	+31.07%	12.02B

Bio Therapeutic Drugs